* Bellerophon Therapeutics Inc BLPH.OQ BLPH.O is
expected
to show no change in quarterly revenue when it reports
results on November 14 (estimated).
*
* Refinitiv's mean analyst estimate for Bellerophon
Therapeutics
Inc is for a loss of 58 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Bellerophon
Therapeutics Inc is $24.5, above its last closing price
of $1.17.
This summary was machine generated November 11 at 14:47 GMT.
All figures in US dollars unless otherwise stated